Since the introduction of Empagliflozin, an SGLT2 inhibitor (Jardiance) to the tool box for the management of type 2 diabetes in February, there has been a small but noticeable national increase in the number of people presenting to hospital in euglycaemic diabetic ketoacidosis.
The cause for this is twofold:
It is advisable to provide written information regarding sick day management when initiating Jardiance, which can be found on our diabetes sick day advice resource or in several languages including Te Reo, Tongan or Samoan on the Health Navigator New Zealand website.
The renal and cardiovascular benefits of an SGLT2 inhibitor far out weigh the risks associated with using it, and with the GLP1 receptor agonist Dulaglutide (Trulicity) now being added as a funded medication, the outlook for diabetes management in New Zealand is more promising.
Kathy Knight, Clinical Diabetes Specialist
027 642 5846
Jessica Knight, Nurse Lead - Taranaki
027 241 1050
Kim Cameron, Clinical Nurse Specialist - Diabetes
027 249 3342